Certolizumab pegol in the treatment of Crohn's disease

Bibliography

• Xavier RJ, Podolsky DK. Unravelling the pathogenesis of inflammatory bowel disease. Nature 2007;448:427-34
   PubMed Web of Science ®Google Scholar
• Louis E, Collard A, Oger AF, Behaviour of Crohn's disease according to the Vienna classification: changing pattern over the course of the disease. Gut 2001;49:777-82
   PubMed Web of Science ®Google Scholar
• Sandborn WJ. Current directions in IBD therapy: what goals are feasible with biological modifiers? Gastroenterology 2008;135:1442-7
   PubMed Web of Science ®Google Scholar
• Colombel JF, Sandborn WJ, Rutgeerts P, Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007;132:52-65
   PubMed Web of Science ®Google Scholar
• Colombel JF, Sandborn WJ, Reinisch W, Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010;362:1383-95
   PubMed Web of Science ®Google Scholar
• Feagan BG, Panaccione R, Sandborn WJ, Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: results from the CHARM study. Gastroenterology 2008;135:1493-9
   PubMed Web of Science ®Google Scholar
• Hanauer SB, Feagan BG, Lichtenstein GR, Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002;359:1541-9
   PubMed Web of Science ®Google Scholar
• Hanauer SB, Sandborn WJ, Rutgeerts P, Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 2006;130:323-33
   PubMed Web of Science ®Google Scholar
• Lichtenstein GR, Yan S, Bala M, Hanauer S. Remission in patients with Crohn's disease is associated with improvement in employment and quality of life and a decrease in hospitalizations and surgeries. Am J Gastroenterol 2004;99:91-6
   PubMed Web of Science ®Google Scholar
• Present DH, Rutgeerts P, Targan S, Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999;340:1398-405
   PubMed Web of Science ®Google Scholar
• Rutgeerts P, D'Haens G, Targan S, Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology 1999;117:761-9
   PubMed Web of Science ®Google Scholar
• Rutgeerts P, Van Assche G, Sandborn WJ, Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial. Gastroenterology 2012;142:1102-11
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Hanauer SB, Rutgeerts P, Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut 2007;56:1232-9
   PubMed Web of Science ®Google Scholar
• Sands BE, Anderson FH, Bernstein CN, Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 2004;350:876-85
   PubMed Web of Science ®Google Scholar
• Baert F, Noman M, Vermeire S, Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003;348:601-8
   PubMed Web of Science ®Google Scholar
• Nesbitt A, Fossati G, Bergin M, Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor alpha agents. Inflamm Bowel Dis 2007;13:1323-32
   PubMed Web of Science ®Google Scholar
• Veronese FM, Mero A. The impact of PEGylation on biological therapies. BioDrugs 2008;22:315-29
   PubMed Web of Science ®Google Scholar
• Chapman AP. PEGylated antibodies and antibody fragments for improved therapy: a review. Adv Drug Deliv Rev 2002;54:531-45
   PubMed Web of Science ®Google Scholar
• Eddleston A, Marenzama M, Marshall D, Nesbitt A. Comparison of the distribution of an IgG and a pegylated Fab' form of an anti-TNFa antibody in the inflamed gut of colitic mice. Gut 2009;58:A305
   Google Scholar
• Palframan R, Airey M, Moore A, Use of biofluorescence imaging to compare the distribution of certolizumab pegol, adalimumab, and infliximab in the inflamed paws of mice with collagen-induced arthritis. J Immunol Methods 2009;348:36-41
   PubMed Web of Science ®Google Scholar
• Bourne T, Fossati G, Nesbitt A. A PEGylated Fab' fragment against tumor necrosis factor for the treatment of Crohn disease: exploring a new mechanism of action. BioDrugs 2008;22:331-7
   PubMed Web of Science ®Google Scholar
• Lamour S, Bracher M, Nesbitt A. Effect of PEG component of certolizumab pegol on stimulated mast cell degranulation. Gut 2009;58:A305
   Google Scholar
• Derer S, Till A, Haesler R, mTNF reverse signalling induced by TNFalpha antagonists involves a GDF-1 dependent pathway: implications for Crohn's disease. Gut 2013; [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Schreiber S, Rutgeerts P, Fedorak RN, A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. Gastroenterology 2005;129:807-18
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Feagan BG, Stoinov S, Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med 2007;357:228-38
   PubMed Web of Science ®Google Scholar
• Schreiber S, Khaliq-Kareemi M, Lawrance IC, Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med 2007;357:239-50
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Abreu MT, D'Haens G, Certolizumab pegol in patients with moderate to severe Crohn's disease and secondary failure to infliximab. Clin Gastroenterol Hepatol 2010;8:688-95
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Schreiber S, Feagan BG, Certolizumab pegol for active Crohn's disease: a placebo-controlled, randomized trial. Clin Gastroenterol Hepatol 2011;9:670-84
   PubMed Web of Science ®Google Scholar
• Winter TA, Wright J, Ghosh S, Intravenous CDP870, a PEGylated Fab' fragment of a humanized antitumour necrosis factor antibody, in patients with moderate-to-severe Crohn's disease: an exploratory study. Aliment Pharmacol Ther 2004;20:1337-46
   PubMed Web of Science ®Google Scholar
• Schreiber S, Colombel JF, Bloomfield R, Increased response and remission rates in short-duration Crohn's disease with subcutaneous certolizumab pegol: an analysis of PRECiSE 2 randomized maintenance trial data. Am J Gastroenterol 2010;105:1574-82
   PubMed Web of Science ®Google Scholar
• Lichtenstein G, Thomsen O, Schreiber S, Long-term remission with certolizumab pegol in Crohn's disease: efficacy over 4.5 years in patients with no prior TNF inhibitor exposure (PRECiSE 3 Study). Am J Gastroenterol 2010;105:S417-18
   Web of Science ®Google Scholar
• Vermeire S, Schreiber S, Sandborn WJ, Correlation between the Crohn's disease activity and Harvey-Bradshaw indices in assessing Crohn's disease severity. Clin Gastroenterol Hepatol 2010;8:357-63
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Schreiber S, Hanauer SB, Reinduction with certolizumab pegol in patients with relapsed Crohn's disease: results from the PRECiSE 4 study. Clin Gastroenterol Hepatol 2010;8:696-702
   PubMed Web of Science ®Google Scholar
• Hanauer SB, Panes J, Colombel JF, Clinical trial: impact of prior infliximab therapy on the clinical response to certolizumab pegol maintenance therapy for Crohn's disease. Aliment Pharmacol Ther 2010;32:384-93
   PubMed Web of Science ®Google Scholar
• eHbuterne X, Lemann M, Endoscopic improvement of mucosal lesions in patients with moderate to severe ileocolonic Crohn's disease following treatment with certolizumab pegol. Gut 2013;62:201-8
   PubMed Web of Science ®Google Scholar
• Vavricka SR, Schoepfer AM, Bansky G, Efficacy and safety of certolizumab pegol in an unselected Crohn's disease population: 26-week data of the FACTS II survey. Inflamm Bowel Dis 2011;17:1530-9
   PubMed Web of Science ®Google Scholar
• Rutgeerts P, Schreiber S, Feagan B, Certolizumab pegol, a monthly subcutaneously administered Fc-free anti-TNFalpha, improves health-related quality of life in patients with moderate to severe Crohn's disease. Int J Colorectal Dis 2008;23:289-96
   PubMed Web of Science ®Google Scholar
• Reilly MC, Gerlier L, Brabant Y, Brown M. Validity, reliability, and responsiveness of the work productivity and activity impairment questionnaire in Crohn's disease. Clin Ther 2008;30:393-404
   PubMed Web of Science ®Google Scholar
• Feagan BG, Reilly MC, Gerlier L, Clinical trial: the effects of certolizumab pegol therapy on work productivity in patients with moderate-to-severe Crohn's disease in the PRECiSE 2 study. Aliment Pharmacol Ther 2010;31:1276-85
   PubMed Web of Science ®Google Scholar
• Feagan BG, Sandborn WJ, Wolf DC, Randomised clinical trial: improvement in health outcomes with certolizumab pegol in patients with active Crohn's disease with prior loss of response to infliximab. Aliment Pharmacol Ther 2011;33:541-50
   PubMed Web of Science ®Google Scholar
• Vavricka SR, Bentele N, Scharl M, Systematic assessment of factors influencing preferences of Crohn's disease patients in selecting an anti-tumor necrosis factor agent (CHOOSE TNF TRIAL). Inflamm Bowel Dis 2012;18:1523-30
   PubMed Web of Science ®Google Scholar
• Simister NE. Placental transport of immunoglobulin G. Vaccine 2003;21:3365-9
   PubMed Web of Science ®Google Scholar
• Mahadevan U, Wolf DC, Dubinsky M, Placental transfer of anti-tumor necrosis factor agents in pregnant patients with inflammatory Bowel disease. Clin Gastroenterol Hepatol 2013; [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Wakefield I, Stephens S, Foulkes R, The use of surrogate antibodies to evaluate the developmental and reproductive toxicity potential of an anti-TNFalpha PEGylated Fab' monoclonal antibody. Toxicol Sci 2011;122:170-6
   PubMed Web of Science ®Google Scholar
• Schnitzler F, Fidder H, Ferrante M, Outcome of pregnancy in women with inflammatory bowel disease treated with antitumor necrosis factor therapy. Inflamm Bowel Dis 2011;17:1846-54
   PubMed Web of Science ®Google Scholar
• Danese S, Mocciaro F, Guidi L, Successful induction of clinical response and remission with certolizumab pegol in Crohn's disease patients refractory or intolerant to infliximab: a real-life multicenter experience of compassionate use. Inflamm Bowel Dis 2008;14:1168-70
   PubMed Web of Science ®Google Scholar
• Allez M, Vermeire S, Mozziconacci N, The efficacy and safety of a third anti-TNF monoclonal antibody in Crohn's disease after failure of two other anti-TNF antibodies. Aliment Pharmacol Ther 2010;31:92-101
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Colombel JF, Enns R, Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med 2005;353:1912-25
   PubMed Web of Science ®Google Scholar